BMO Capital analyst Keith Bachman maintains Splunk (NASDAQ:SPLK) with a Outperform and lowers the price target from $120 to $100.
Glucotrack Announces Increased Sensor Longevity For Its Implantable Continuous Blood Glucose Monitor
Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announcedImplantable Continuous Blood Glucose Monitor technology could transform lives of
